A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS

Clinical trial NCT05424380 · TERMINATED

Trial details

NCT number: NCT05424380
Sponsor: GlaxoSmithKline
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Leukemia, Myeloid, Acute

Start date: 2022-09-20
Primary completion: 2024-03-04
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.